Gilead Sciences, Inc. $GILD Holdings Decreased by Guggenheim Capital LLC

Key Points

• Guggenheim Capital LLC reduced its stake in Gilead Sciences, Inc. by 17.9% during the first quarter, selling 116,029 shares and now holding 531,224 shares.
• Gilead Sciences has seen positive sentiment from analysts, with organizations like Daiwa and Needham & Company LLC upgrading their ratings and price targets for the stock.
• The company recently declared a quarterly dividend of $0.79 per share, with a dividend yield of 2.8% and a payout ratio of 62.95%.

Guggenheim Capital LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 531,224 shares of the biopharmaceutical company's stock after selling 116,029 shares during the period. Gilead Sciences accounts for approximately 0.5% of Guggenheim Capital LLC's portfolio, making the stock its 28th biggest holding. Guggenheim Capital LLC's holdings in Gilead Sciences were worth $59,524,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences in the 1st quarter worth about $25,000. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences in the 1st quarter worth about $29,000. Colonial Trust Advisors boosted its stake in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 213 shares during the last quarter. Core Alternative Capital boosted its stake in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares during the last quarter. Finally, IMA Advisory Services Inc. acquired a new stake in Gilead Sciences in the 1st quarter worth about $39,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the sale, the chief executive officer directly owned 595,725 shares in the company, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares of the company's stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,371,330 over the last 90 days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Up 0.4%

Shares of NASDAQ:GILD traded up $0.41 during mid-day trading on Friday, hitting $112.97. 4,629,720 shares of the company traded hands, compared to its average volume of 6,327,395. The firm has a market cap of $140.17 billion, a P/E ratio of 22.50, a PEG ratio of 0.70 and a beta of 0.33. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 52-week low of $77.74 and a 52-week high of $121.83. The firm's 50 day simple moving average is $113.01 and its 200 day simple moving average is $109.63.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the previous year, the business earned $2.01 EPS. Gilead Sciences's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences's payout ratio is currently 62.95%.

Analyst Ratings Changes

A number of analysts have issued reports on GILD shares. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their price target for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. Finally, UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.